

Case #3364/1 (PHA 4176)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

David L. Brown, et. al.

SERIAL NO: 09/839,424

FILED: April 20, 2001

GROUP ART UNIT: 1625

EXAMINER: B. Dentz

DATE: July 20, 2005

TITLE: 2-Fluorobenzensulfonyl Compounds for the Treatment
of Inflammation

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner for Patents
Alexandria, VA 22313

Dear Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Philip B. Polster, II
Attorney for Applicants
Registration No. 43,864
Tel: 314-274-9094

Pharmacia Corporation
of Pfizer Inc
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63306

(Form PTO-1449)

Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3364/1 (PHA 4176)	APPLICATION NO. 09/839,424
	INVENTOR: Brown, et. al.	
	Filed: 4/20/01	Group: 1625

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]


EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

(Form PTO-1449)

TO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Sheet	3	of	8	Attorney Docket No.	3364(PHA 4176)
-------	---	----	---	---------------------	----------------

Application Number 09/839,424

Filing Date 04-20-2001

Confirmation Number 1761

First Named Inventor D. Brown

Group Art Unit 1614

Examiner Name TBA

30	5,639,777	B1	Lee	06-17-1997
31	5,663,180	B1	Reitz et al.	09-02-1997
32	5,668,161	B1	Talley et al.	09-16-1997
33	5,670,510	B1	Huang et al.	09-23-1997
34	5,672,626	B1	Huang et al.	09-30-1997
35	5,672,627	B1	Huang et al.	09-30-1997
36	5,719,163	B1	Norman et al.	02-17-1998
37	5,736,579	B1	Reitz et al.	04-07-1998
38	5,739,166	B1	Reitz et al.	04-14-1998
39	5,756,529	B1	Isakson et al.	05-26-1998
40	5,760,068	B1	Talley et al.	06-02-1998
41	5,859,036	B1	Sartori et al.	01-12-1999
42	5,859,257	B1	Talley	01-12-1999
43	5,886,016	B1	Talley et al.	03-23-1999
44	5,908,852	B1	Talley et al.	06-01-1999
45	5,916,905	B1	Weier et al.	06-29-1999
46	5,932,598	B1	Talley et al.	08-03-1999

Examiner
SignatureDate
Considered

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard P.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation attached.


Order Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

TO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		09/839,424
				Filing Date		04-20-2001
				Confirmation Number		1761
				First Named Inventor		D. Brown
				Group Art Unit		1614
				Examiner Name		TBA
				Sheet	4	of

	47	5,935,990	B1	Khanna et al.	08-10-1999		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
**	48	EP	197704	A2	GEC Avinoics Limited	10-15-1986	
**	49	EP	26928	A1	CDC Life Sciences Inc.	04-15-1981	
**	50	EP	745596	A1	Japan Tobacco, Inc.	12-04-1996	
	51	EP	799823	A1	Sankyo Company Limited	10-08-1997	
	52	GB	2294879	A	Merck & Co Inc.	05-15-1996	
	53	JP	1045374	A	Kokusai Shiyaku KK (abstract)	02-17-1989	
	54	JP	4277724	A	Sumitomo Electric Ind. Ltd. (abstract)	10-02-1992	
	55	JP	5323522	A	Fuji Photo Film Co Ltd. (abstract)	12-07-1993	
	56	WO	92/05162	A1	Taiho Pharmaceutical Co., Ltd.	04-02-1992	
	57	WO	92/19604	A1	Taiho Pharmaceutical Co., Ltd.	11-12-1992	
	58	WO	93/14082	A1	Smith-Kline Beecham Corporation	07-22-1993	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation attached.


Ordin Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

TO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/839,424
				Filing Date	04-20-2001
				Confirmation Number	1761
				First Named Inventor	D. Brown
				Group Art Unit	1614
				Examiner Name	TBA
				Sheet	5

	59	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994	
	60	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994	
	61	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994	
	62	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994	
	63	WO	95/00501	A2	Merck Frosst Canada Inc.	01-05-1995	
	64	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995	
	65	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995	
	66	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996	
	67	WO	96/03388	A1	G.D. Searle & Co.	02-08-1996	
	68	WO	96/09293	A1	G.D. Searle & Co.	03-28-1996	
	69	WO	96/19462	A1	Japan Tobacco Inc. (abstract)	06-27-1996	
	70	WO	96/19463	A1	Japan Tobacco Inc. (abstract)	06-27-1996	
	71	WO	96/36617	A1	G.D. Searle & Co.	11-21-1996	
	72	WO	96/37476	A1	G.D. Searle & Co.	11-28-1996	
	73	WO	97/16435	A1	Merck Frosst Canada Inc.	05-09-1997	
	74	WO	97/25045	A1	SmithKline Beecham Corporation	07-17-1997	
	75	WO	97/25047	A1	SmithKline Beecham Corporation	07-17-1997	

 Examiner
Signature

 Date
Considered

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard P.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document and the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation attached.

Order Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

TO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/839,424
				Filing Date	04-20-2001
				Confirmation Number	1761
				First Named Inventor	D. Brown
				Group Art Unit	1614
				Examiner Name	TBA
				Sheet 6 of 8	Attorney Docket No.

	76	WO	97/25048	A1	SmithKline Beecham Corporation	07-17-1997	
	77	WO	98/03484	A1	Merck Frosst Canada Inc.	01-29-1998	
	78	WO	98/07425	A1	SmithKline Beecham Corporation	02-26-1998	
	79	WO	98/11080	A1	Laboratories UPSA	03-19-1998	
	80	WO	98/22442	A1	Angelini Recherche S.p.A.	05-28-1998	
	81	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
	82	WO	99/14205	A1	Almirall Prodesfarma SA	03-25-1999	
	83	WO	99/64415	A1	Pfizer Inc.	12-16-1999	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	84	NASJLETTI, A. "The Role of Eicosanoids in Angiotensin-Dependent Hypertension." Hypertension, 1998, pp. 194-200, Vol. 31, No. 1, Part 2..	
	85	AHLUWALIA, et al., "Mechanism of the Debromination in Heteocyclization Using a,a-Dibromocarbonyl Compounds as Synthons." Synth. Commun., 1989, pp. 619-626, Vol. 19, Nos. 3&4.	
	86	MUKERJEE et al., "Synthesis of Some Formazans and tetrazolium salts as antiviral agents." Acta. Pharma. Jugosl., 1981, pp. 151-158, Vol. 31.	
		SPEIR et al., "Aspirin Attenuates Cytomegalovirus Infectivity and Gene Expression Mediated by	

Examiner
SignatureDate
Considered

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard I.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation attached.

Ordinary Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

TO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/839,424
				Filing Date	04-20-2001
				Confirmation Number	1761
				First Named Inventor	D. Brown
				Group Art Unit	1614
				Examiner Name	TBA
				Sheet 7 of 8	Attorney Docket No.

87	Cyclooxygenase-2 in Coronary Artery Smooth Muscle Cells." Circ. Res., 1998, pp. 210-216, Vol. 83, No. 2.	
88	BAGETTA et al., "HIV-1 gp120-Induced Apoptosis in the Rat Neocortex Involves Enhanced Expression of Cyclo-Oxygenase Type 2 (Cox-2)." Biochem. Biophys. Res. Commun., 1998, pp. 819-824, Vol. 244.	
89	DOROFENKO et al., Khim. Farm. Zh., 1982, pp. 920-921, Vol. 16.	
90	GIERSE et al., "Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase." J. Biochem, 1995, pp. 479-484, Vol. 305, Part 2.	
91	BOSCH, et al., "Efficacy and Tolerability of Intramuscular and Oral Meloxicam in Patients with Acute Lumbago: A Comparison with Intramuscular and Oral Piroxicam." Curr. Med. Res. Opin., 1997, pp 29-38, Vol. 14, No. 1.	
92	FAID-ALLAH et al., "Pyrazole Derivatives with Possible Hypoglycemic Activity." Ind. J. Chem., 1988, pp. 245-249, Vol. 27.	
93	HARGREAVES et al., "A New and Sensitive Method for Measuring thermal Nociception in Cutaneous Hyperalgesia." Pain, 1988, pp. 77-88, Vol. 32.	
94	HUANG, et al., "A Novel One-Pot Conversion of Methyl Sulfones to Sulfonamides." Tetrahedron Letters, 1994, pp. 7201-7204, Vol. 35, No. 39.	
95	SINGER et al., "Cyclooxygenase 2 Is Induced in Colonic Epithelial Cells in Inflammatory Bowel Disease." Gastroenterology, 1998, pp. 297-306, Vol. 115, No. 2.	
96	MIYAMOTO et al., "The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis." Neuro Report, 1998, pp. 2331-2334, Vol. 9, No. 10.	
97	SUBBARAMAIAH et al., "Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention (44170)." Proc. Soc. Exp. Biol. Med., 1997, pp. 201-210, Vol. 216, No. 2.	

Examiner Signature	Date Considered
--------------------	-----------------

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard F.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation attached.

Estimated Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

TO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/839,424
				Filing Date	04-20-2001
				Confirmation Number	1761
				First Named Inventor	D. Brown
				Group Art Unit	1614
				Examiner Name	TBA
				Sheet	8

	98	WILSON, et al., "Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett's Esophagus and Associated Adenocarcinomas." Cancer Res., 1998, pp. 2929-2934, Vol. 58, No. 14.	
	99	KHARASCH, et al., "Derivatives of Sulfenic Acids. V. I-Fluorenone Sulfur Compounds." Am. Chem. Soc., 1951, pp. 3240-3244, Vol. 73, No. 7.	
	100	BUSTOS, et al., "Modulation of Eicosanoid Metabolism in Endothelial Cells in a Xenograft Model." J. Clin. Invest., 1997, pp 1150-1158, Vol. 100, No. 5.	
	101	SHOUP, et al., "Cyclooxygenase-2 Inhibitor NS-398 Improves Survival and Restores Leukocyte Counts in Burn Infection." J. Trauma: Inj. Infeec., Crit Care, 1998, pp 215-221, Vol. 45, No. 2.	
	102	TSUJII et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells." Cell, 1998, pp. 705-716, Vol. 93, No. 5.	
	103	BARNES et al., "Cyclooxygenase-2 Expression in Airway Cells." Lung Biol. Health Dis, 1998, pp. 111-127, Vol. 114.	
	104	REID, et al., "Some New β -Diketones Containing the Trifluoromethyl Group." J. Amer. Chem. Soc., 1950, pp 2948-2952, Vol. 72, No. 7.	
	105	BUCKMAN et al., "Cox-2 Expression is Induced by UVB Exposure in Human Skin: Implications for the development of skin cancer." Carcinogenesis, 1998, pp. 723-729, Vol. 19, No. 5.	
	106	NOGAWA et al., "Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia." Proc. Natl. Acad. Sci., 1998, pp. 10966-10971, Vol. 95, No. 18.	
	107	DIKSHIT, et al., "Synthesis and biological activity of 2,3- and 3,4-diarylfurans and 2,3,4-triaryl-2,5-dihydrofurans." Indian J. Chem, Sect. B, 1990, pp 954-960, Vol. 29B, No. 10.	
	108	MIYAURA, et al., "The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases." Synth. Commun., 1981, pp. 513-519, Vol. 11, No. 7.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard F.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document and the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation attached.

Ordinary Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.